CN101973998A — 吡咯并嘧啶A2b选择性拮抗剂化合物
Assigned to OSI Pharmaceuticals LLC · Expires 2011-02-16 · 15y expired
What this patent protects
吡咯并嘧啶A 2b 选择性拮抗剂化合物,它们的合成及用途,一种具有下面结构的化合物,其中R 1 为取代或未取代的烷基,其中取代基为羟基,二羟基,羰基,-C(=O)NR a R b ,-NR a R b ,-NRaC(=O)NR a R b ,-NR a C(=O)OR a ,-OC(=O)NR a R b ,或-NHC(=O)R a ;R 2 为氢或取代或未取代的烷基,其中取代基为羟基,二羟基,羰基,-C(=O)NR a R b ,-NR a R b ,-NR a C(=O)NR a R b ,-NR a C(=O)OR a ,-OC(=O)NR a R…
USPTO Abstract
吡咯并嘧啶A 2b 选择性拮抗剂化合物,它们的合成及用途,一种具有下面结构的化合物,其中R 1 为取代或未取代的烷基,其中取代基为羟基,二羟基,羰基,-C(=O)NR a R b ,-NR a R b ,-NRaC(=O)NR a R b ,-NR a C(=O)OR a ,-OC(=O)NR a R b ,或-NHC(=O)R a ;R 2 为氢或取代或未取代的烷基,其中取代基为羟基,二羟基,羰基,-C(=O)NR a R b ,-NR a R b ,-NR a C(=O)NR a R b ,-NR a C(=O)OR a ,-OC(=O)NR a R b ,或-NHC(=O)R a ,或R 1 ,R 2 和N一起形成取代的哌嗪,取代的氮杂环丁烷,或吡咯烷环,其被-(CH 2 ) 2 OH或-CH 2 C(=O)OH所取代;R 3 为取代或未取代的苯基或5-6元杂环,其中取代基为卤素,羟基,氰基,(C 1 -C 15 )烷基,(C 1 -C 15 )烷氧基,或-NR a R b ;R 4 为氢或取代的或未取代的(C 1 -C 15 )烷基;R 5 为-(CH 2 ) m OR 6 ,-CHNOR 7 ,-C(=O)NR 8 R 9 ,-(CH 2 ) m C(=O)OR 10 ,-(CH 2 ) k C(=O)NR 11 R 12 。
Drugs covered by this patent
- Balversa (ERDAFITINIB) · Johnson & Johnson
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.